ARTA
CRSP icon

A.R.T. Advisors’s CRISPR Therapeutics CRSP Stock Holding History

A.R.T. Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,926
Closed -$235K – 21
2021
Q1 		$235K Buy
+1,926
New +$291K 1.28% 32
2020
Q1 		– Sell
-16,526
Closed -$1.01M – 265
2019
Q4 		$1.01M Buy
+16,526
New +$902K 0.05% 557
2019
Q2 		– Sell
-36,026
Closed -$1.29M – 1390
2019
Q1 		$1.29M Buy
+36,026
New +$1.25M 0.08% 390
2018
Q2 		– Sell
-20,655
Closed -$944K – 1480
2018
Q1 		$944K Sell
20,655
-3,800
-16% -$157K 0.04% 689
2017
Q4 		$574K Buy
+24,455
New +$465K 0.03% 836

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

A.R.T. Advisors's CRSP Position: Q2 2021 in Review

A.R.T. Advisors sold out of CRISPR Therapeutics (CRSP) in Q2 2021, closing a stake of 1,926 shares — an estimated $235K sold.

A.R.T. Advisors first reported a position in CRSP in Q4 2017 and held it in 5 quarters. The position peaked at $1.29M in Q1 2019. 498 funds tracked by Wall St. Rank hold CRSP as of Q2 2021.

  • A.R.T. Advisors reported no remaining CRISPR Therapeutics position as of Q2 2021 after selling out during the quarter.
  • A.R.T. Advisors sold 1,926 CRISPR Therapeutics shares in Q2 2021, an estimated $235K.
  • A.R.T. Advisors first reported a position in CRISPR Therapeutics in Q4 2017 and held it in 5 quarters.
  • A.R.T. Advisors's CRISPR Therapeutics position peaked at $1.29M in Q1 2019.
  • 498 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2021.

Based on A.R.T. Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.